Depression in patients recovering from a myocardial infarction

JAMA

Volumn 286, Issue 13, 2001, Pages 1621-1627

  Ziegelstein, R C ^a  

^a JOHNS HOPKINS BAYVIEW MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; DEPRESSION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART REHABILITATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SOCIAL SUPPORT; SYMPTOMATOLOGY; THROMBOCYTE ACTIVATION;

EID: 0035802271     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.286.13.1621     Document Type: Article

References (49)

1. An inventory for measuring depression
2. Depression and 18-month prognosis after myocardial infarction
3. The Hospital Anxiety and Depression Scale
4. Construct validation of the hospital anxiety and depression scale with clinical populations
5. Depression after myocardial infarction
6. The nature and course of depression following myocardial infarction
7. Depression following myocardial infarction
8. Patients with depression are less likely to follow recommendations to reduce cardiac risk during recovery from a myocardial infarction
9. Do depression and anxiety predict recurrent coronary events 12 months after myocardial infarction?
10. Personality and mortality after myocardial infarction
11. Affective disorders and survival after acute myocardial infarction: Results from the post-infarction late potential study
12. Effects of depression and anxiety on mortality and quality-of-life 4 months after myocardial infarction
13. Mortality and quality of life 12 months after myocardial infarction: Effects of depression and anxiety
14. Social support, depression, and mortality during the first year after myocardial infarction
15. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction
16. Independent importance of psychosocial factors for prognosis after myocardial infarction
17. Relation between myocardial infarction, depression, hostility, and death
18. Depression and risk of sudden cardiac death after acute myocardial infarction: Testing for the confounding effects of fatigue
19. Depression and anxiety as predictors of outcome after myocardial infarction
20. Psychological response to an acute coronary event and its effect on subsequent rehabilitation and lifestyle change
21. Physiological and psychological variables predict compliance to prescribed exercise therapy in patients recovering from myocardial infarction
22. Major depression and medication adherence in elderly patients with coronary artery disease
23. Severe depression is associated with markedly reduced heart rate variability in patients with stable coronary heart disease
24. Change in heart rate and heart rate variability during treatment for depression in patients with coronary heart disease
25. Platelet reactivity in depressed patients treated with paroxetine: Preliminary findings
26. Platelet activation in depression and effects of sertraline treatment: An open-label study
27. Platelet cytosolic calcium responses to serotonin in depressed patients and controls: Relationship to symptomatology and medication
28. Platelet phosphoinositide signaling system: An overstimulated pathway in depression
29. Mental disorders and use of cardiovascular procedures after myocardial infarction
30. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence
31. Impact of medication nonadherence on coronary heart disease outcomes
32. Treatment adherence and risk of death after a myocardial infarction
33. Decreased heart rate variability and its association with mortality after myocardial infarction
34. Frequency domain measures of heart period variability to assess risk late after myocardial infarction
35. Enhancing recovery in coronary heart disease patients (ENRICHD): Study design and methods
36. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial): Sertraline Anti-Depressant Heart Attack Trial
37. Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease
38. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction
39. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: A meta-analysis
40. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials
41. The safety of tricyclic antidepressants in cardiac patients: Risk-benefit reconsidered
42. Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease
43. Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: Findings from a double-blind, placebo-controlled trial
44. Effects of cardiac rehabilitation and exercise training programs on depression in patients after major coronary events
45. A symptom questionnaire
46. Prevalence and effects of cardiac rehabilitation on depression in the elderly with coronary heart disease
47. The multilevel compliance challenge: Recommendations for a call to action, a statement for healthcare professionals
48. Compliance, adherence, concordance